Atrial fibrillation comes back in a substantial minority of the people who have it burned out by catheter ablation, and weight is one of the few things a patient can change that is known to matter. So the question of whether a GLP-1 drug lowers the recurrence rate is not academic: it is the kind of claim a seller could reasonably be tempted to put on a landing page. The evidence, as it stands, will not support one, and the reason why is worth following, because it is the same reason so many claims about this drug class read as more settled than they are — a habit visible on most of the seller pages ranked here.
Two studies, one research network, opposite conclusions
A multicenter analysis published in 2026 drew obese adults without a diabetes requirement from the TriNetX network, matched 3,350 GLP-1 users to 3,350 nonusers across 82 clinical and demographic variables, and followed them a median of two years. Recurrence was 6.66% among users against 7.72% among nonusers, a hazard ratio of 0.82 (95% CI 0.76 to 0.88, P < 0.0001)[1]. Progression to permanent atrial fibrillation was also lower at a hazard ratio of 0.77 (95% CI 0.63 to 0.93), as were all-cause mortality at 0.73 (95% CI 0.59 to 0.91) and heart-failure hospitalization at 0.80 (95% CI 0.71 to 0.90).
An earlier analysis, published in 2024, used the same TriNetX network to ask a question that sounds identical. It matched 1,625 preablation GLP-1 users to 1,625 nonusers and followed a composite of cardioversion, a new antiarrhythmic drug, or a repeat ablation over twelve months after a three-month blanking period. The hazard ratio was 1.04 (95% CI 0.92 to 1.19, log-rank P = 0.51) [2], and stroke, hospitalization and mortality did not differ either. The authors concluded the evidence does not support a benefit and called for research that would settle it.
What differs is who was counted, and for how long
The two cohorts are not the same people asked the same question. The 2026 analysis required a body mass index above 30 and excluded nobody on the basis of diabetes; the 2024 analysis took every adult undergoing ablation in the window it covered. The follow-up differs by a factor of two, and the outcome definitions differ as well: one counted recurrence, the other counted a composite of three downstream interventions that a clinician chooses. Body mass index is doing work of its own here: it is the variable the newer cohort selected on, and the one every pooled weight-loss estimate is built from. Either study could be right about its own population without contradicting the other, which is a more uncomfortable finding than a straightforward disagreement would be, because it means neither result generalizes cleanly to the person reading it.
This shape recurs across the literature on these drugs, and we have written about it before where two meta-analyses drew opposite conclusions from the same six trials and where studies of blood-vessel function returned two answers. The pattern is not fraud and it is rarely even error. It is what happens when a large observational database is asked a question the underlying data was not collected to answer.
What a buyer should take from it
Nothing on this page is a reason to start or stop a prescription, and nobody should be buying a GLP-1 drug in order to treat an arrhythmia. What it is useful for is calibration. If a seller's page ever cites a cardiac benefit as a reason to buy, the honest version of that claim carries the population it was measured in and the length of the follow-up, and almost none of them do — an absence we have counted across the market in what sellers do not publish.
The practical question a buyer can actually act on is a duller one: who is writing the prescription, what they know about your heart, and whether the service you are paying makes that person reachable. Those are the questions worth taking to an intake, and we keep a list of them in questions they leave open.